ArticleAdvances in laboratory medicine2022
The study of the role of insulin resistance as etiological factor in polycystic ovarian syndrome: a case control study.
Article in Advances in laboratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Polycystic Ovary Syndrome and Oxidative Stress-From Bench to Bedside.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The relationship between insulin resistance (IR) and polycystic ovary syndrome (PCOS) has been consistently shown by several studies but what is the cause and what is the effect remained an unsolved issue. In recent years, IR has been suggested to be a key etiological factor which contributes to the severity of metabolic and reproductive features in PCOS. The aim of the present study is to determine the etiological role of IR in PCOS. Methods: This is an analytical case control study where 30 newly diagnosed normoglycemic cases of PCOS (according to Rotterdam revised criteria 2003) between the age group of 15 and 35 years were enrolled. A total of 30 age matched, apparently healthy women were selected from volunteers as controls. Fasting glucose was analysed by spectrophotometry and fasting insulin by chemiluminescence immunoassay. HOMA-IR, Log HOMA-IR, QUICKI, G/I ratio and FIRI were calculated using standard formulae. Results: The anthropometric parameters and markers of IR were high and QUICKI & G/I ratio were low in cases as compared to controls (p<0.05). Cases with BMI≥25 showed significantly higher IR markers and lower QUICKI & G/I ratio than BMI<25 cases and BMI matched controls. No significant difference was present in IR markers between high and low central obesity cases. Conclusions: The findings of our study suggest that in normoglycemic PCOS women, raised IR markers in obese patients cannot be attributed to obesity or central obesity alone. Presence of IR in newly diagnosed cases at such an early stage i.e., even before development of hyperglycemia and hyperinsulinemia suggest IR to be a causative factor in development of PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.